{
    "2021-06-08": [
        [
            {
                "time": "",
                "original_text": "医美细分Ⅰ：再生元年的针剂趋势",
                "features": {
                    "keywords": [
                        "医美",
                        "再生元",
                        "针剂",
                        "趋势"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "美容"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "华东医药复方降糖药二甲双胍恩格列净获批 原研药首次迎来对手",
                "features": {
                    "keywords": [
                        "华东医药",
                        "复方降糖药",
                        "二甲双胍",
                        "恩格列净",
                        "原研药",
                        "获批"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "速读社丨FDA批准阿尔茨海默病药Aduhelm 恒瑞、阿斯利康等多款重磅药物新适应症即将获批",
                "features": {
                    "keywords": [
                        "FDA",
                        "阿尔茨海默病",
                        "Aduhelm",
                        "恒瑞",
                        "阿斯利康",
                        "重磅药物",
                        "新适应症",
                        "获批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药",
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}